Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625709 | 0.89 | MET (0.39) | MEN1KMT2APOLBTDP1P2RX7 | |
| SCHEMBL16627462 | 0.89 | KMT2A (0.43) | MEN1KMT2APOLBTDP1NPC1 | |
| SCHEMBL13558506 | 0.88 | MAP2K1 (0.40) | MEN1KMT2APOLBTDP1NPC1 | |
| SCHEMBL16627464 | 0.87 | MEN1 (0.41) | MEN1KMT2APOLBTDP1NPC1 | |
| SCHEMBL10290905 | 0.85 | PDE10A (0.51) | MEN1KMT2ANPC1RAB9APDE10A | |
| SCHEMBL17677297 | 0.80 | KMT2A (0.38) | MEN1KMT2APOLBTDP1NPC1 | |
| SCHEMBL18399502 | 0.80 | KMT2A (0.43) | MEN1KMT2APOLBTDP1NPC1 | |
| SCHEMBL18399508 | 0.78 | KMT2A (0.41) | MEN1KMT2APOLBTDP1NPC1 | |
| SCHEMBL18399541 | 0.78 | KMT2A (0.43) | MEN1KMT2APOLBTDP1NPC1 | |
| SCHEMBL14642195 | 0.78 | MAP2K1 (0.43) | MEN1KMT2APOLBTDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICAL (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | MEN1 3211/4885KMT2A 1900/4885POLB 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.